These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 17942945

  • 21. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 22. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis.
    Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J.
    Lupus; 2009 Jan; 18(1):78-80. PubMed ID: 19074173
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R, Pohle S, Retzlaff K, Hemberger J, Oschmann P.
    Neuroimmunomodulation; 2009 Jan; 16(3):171-6. PubMed ID: 19246939
    [Abstract] [Full Text] [Related]

  • 29. THE GLOMERULUS in the nephrotic syndrome.
    Br Med J; 1959 Aug 22; 2(5146):229-31. PubMed ID: 13671239
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [New treatments for Idiopathic Nephrotic Syndrome].
    Guigonis V.
    Arch Pediatr; 2009 Jun 22; 16(6):802-4. PubMed ID: 19541177
    [No Abstract] [Full Text] [Related]

  • 34. Rituximab and nephrotic syndrome: a new therapeutic hope?
    Ahmed MS, Wong CF.
    Nephrol Dial Transplant; 2008 Jan 22; 23(1):11-7. PubMed ID: 18065825
    [No Abstract] [Full Text] [Related]

  • 35. [Albuminuria due to acetylcholine and its prevention by treatment with a beta-blockader. Its possible relation to the nephrotic syndrome].
    Perosa L, De Cesaris R, Balestrazzi M, Lamorgese V.
    Boll Soc Ital Biol Sper; 1977 Sep 15; 53(17):1411-3. PubMed ID: 607951
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study.
    Clin Ther; 2009 Aug 15; 31(8):1724-36. PubMed ID: 19808131
    [Abstract] [Full Text] [Related]

  • 38. Embolia cutis medicamentosa following interferon beta injection.
    Koontz D, Alshekhlee A.
    Mult Scler; 2007 Nov 15; 13(9):1203-4. PubMed ID: 17967846
    [No Abstract] [Full Text] [Related]

  • 39. [Nephrotic syndrome in the elderly. Treatment of the nephrotic syndrome in the elderly (part II)].
    Szmyt M, Niemir ZI, Czekalski S.
    Pol Merkur Lekarski; 2007 Nov 15; 23(137):391-4. PubMed ID: 18361327
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.